ABSORV at Long Term in Daily Practice Lesions

absorv abbottThis work reports one year outcomes of the BVS Expand registry. Multiple studies have shown the safety and feasibility of the everolimus eluting bioresorbable scaffold ABSORB (Abbott Vascular, Santa Clara, California), but medium and long term data are limited and only on simple lesions.

 

This is a prospective single-center registry assessing ABSORB performance in lesions representative of the daily practice, such as:

  • Calcified lesions
  • Total occlusions
  • Long lesions
  • Small vessels

 

Inclusion criteria were patients presenting with non ST elevation MI, stable or unstable angina or silent ischemia caused by de novo stenotic lesions in native coronary arteries.

 

Primary end point were major adverse cardiovascular events (MACE) defined as a composite of:

  • Cardiac death
  • Acute myocardial infarction
  • Target vessel revascularization

 

Between September 2012 and January 2015, 249 patients with 335 lesions were included. The mean number of scaffolds per patient was 1.79 ± 1.15. Invasive imaging was used for scaffold implantation in 39% of patients.

 

Mean follow up was 622 days (376 a 734). Using Kaplan-Meier, at 18 months:

  • MACE rate was 6.8%.
  • Cardiac death rate was 1.8%.
  • AMI rate was 5.2%.
  • Target lesion revascularization rate was 4.0%. Scaffold definite thrombosis rate was 1.9%.

 

Conclusion

In complex patients and lesions, the ABSORB resorbable scaffold showed acceptable performance at long term. There were no cases of early thrombosis.

 

Original Title: Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold. The BVS Expand Registry.

Reference: Cordula M. Felix et al. J Am Coll Cardiol Intv. 2016;9(16):1652-1663.

 

We value your opinion. You are more than welcome to leave your thoughts, comments, questions or suggestions here below.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...